Literature DB >> 19467788

Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives.

Mario Scartozzi1, Alessandro Bittoni, Mirco Pistelli, Eva Galizia, Rossana Berardi, Riccardo Giampieri, Luca Faloppi, Stefano Cascinu.   

Abstract

In the last few years therapeutic options for gastric cancer patients have slowly, but constantly expanded following the introduction of both new chemotherapy agents and innovative indications for treatment. Along with the medical therapy also our knowledge of the molecular mechanisms underlying this disease has progressively improved. However although the available treatment options have undoubtedly increased no clear definitive indications can be made for a standard chemotherapy regimen and we are still unable to accurately select the appropriate treatment for the appropriate patient. Many molecular determinants of response/toxicity to chemotherapy agents have been identified, but only few of them seem to possess the necessary potential for a subsequent application in the clinical practice. Some of these factors have also been indicated as a therapeutic target for a novel class of anti-cancer compounds. This systematic review will analyse available data about these factors with the aim to constitute a starting point for future research.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19467788     DOI: 10.1016/j.ctrv.2009.04.008

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  16 in total

Review 1.  Roles of inflammatory cytokines in the progression of gastric cancer: friends or foes?

Authors:  Hironori Tsujimoto; Satoshi Ono; Takashi Ichikura; Yusuke Matsumoto; Junji Yamamoto; Kazuo Hase
Journal:  Gastric Cancer       Date:  2010-12-03       Impact factor: 7.370

Review 2.  Tumor control versus adverse events with targeted anticancer therapies.

Authors:  Dorothy M K Keefe; Emma H Bateman
Journal:  Nat Rev Clin Oncol       Date:  2011-12-20       Impact factor: 66.675

Review 3.  Anti-HER agents in gastric cancer: from bench to bedside.

Authors:  Lorenzo Fornaro; Maurizio Lucchesi; Chiara Caparello; Enrico Vasile; Sara Caponi; Laura Ginocchi; Gianluca Masi; Alfredo Falcone
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-06-07       Impact factor: 46.802

4.  Predictive and prognostic molecular markers for cancer medicine.

Authors:  Sunali Mehta; Andrew Shelling; Anita Muthukaruppan; Annette Lasham; Cherie Blenkiron; George Laking; Cristin Print
Journal:  Ther Adv Med Oncol       Date:  2010-03       Impact factor: 8.168

5.  Evidence for predictive role of BRCA1 and bTUBIII in gastric cancer.

Authors:  Vladimir M Moiseyenko; Nikita M Volkov; Evgeny N Suspistin; Grigoriy A Yanus; Aglaya G Iyevleva; Ekatherina Sh Kuligina; Alexandr V Togo; Alexandr V Kornilov; Alexandr O Ivantsov; Evgeny N Imyanitov
Journal:  Med Oncol       Date:  2013-03-27       Impact factor: 3.064

Review 6.  Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.

Authors:  J M Campbell; M D Stephenson; E Bateman; M D J Peters; D M Keefe; J M Bowen
Journal:  Pharmacogenomics J       Date:  2016-08-09       Impact factor: 3.550

7.  Quality of life in patients with advanced gastric cancer sequentially treated with docetaxel and irinotecan with 5-fluorouracil and folinic acid (leucovin).

Authors:  M Gubanski; B Glimelius; P A Lind
Journal:  Med Oncol       Date:  2014-03-14       Impact factor: 3.064

8.  LncRNA MBNL1-AS1 represses gastric cancer progression via the TGF-β pathway by modulating miR-424-5p/Smad7 axis.

Authors:  Jiewen Su; Dawei Chen; Yi Ruan; Yuan Tian; Kaiji Lv; Xinhua Zhou; Dongjian Ying; Yeting Lu
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

9.  The expression and clinical significance of miR-132 in gastric cancer patients.

Authors:  Xiaowen Liu; Hongmei Yu; Hong Cai; Yanong Wang
Journal:  Diagn Pathol       Date:  2014-03-12       Impact factor: 2.644

10.  Clinical evidence for three distinct gastric cancer subtypes: time for a new approach.

Authors:  Alessandro Bittoni; Mario Scartozzi; Riccardo Giampieri; Luca Faloppi; Maristella Bianconi; Alessandra Mandolesi; Michela Del Prete; Mirco Pistelli; Luca Cecchini; Italo Bearzi; Stefano Cascinu
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.